We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+4.46%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.63B
AUM Growth
+$3.92M
Cap. Flow
+$439M
Cap. Flow %
6.62%
Top 10 Hldgs %
41.1%
Holding
130
New
17
Increased
26
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$228M
2
PEN icon
Penumbra
PEN
+$104M
3
TNYA icon
Tenaya Therapeutics
TNYA
+$52.8M
4
SGHT icon
Sight Sciences
SGHT
+$42.2M
5
MGNX icon
MacroGenics
MGNX
+$34.4M

Top Sells

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$113M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$74.8M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$54.3M
4
MDXG icon
MiMedx Group
MDXG
+$27.1M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.48%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLU
51
DELISTED
BELLUS Health Inc.
BLU
$30.4M 0.46%
4,968,017
– –
SGHT icon
52
Sight Sciences
SGHT
$412M
$29.1M 0.44%
+1,283,871
New +$42.2M
JNJ icon
53
Johnson & Johnson
JNJ
$625B
$27.5M 0.42%
170,542
– –
GLUE icon
54
Monte Rosa Therapeutics
GLUE
$1.35B
$26M 0.39%
1,214,572
– –
CLSD
55
DELISTED
Clearside Biomedical
CLSD
$25.2M 0.38%
280,451
– –
MIST icon
56
Milestone Pharmaceuticals
MIST
$152M
$24.6M 0.37%
4,315,102
– –
PMVP icon
57
PMV Pharmaceuticals
PMVP
$63.5M
$24.1M 0.36%
809,863
+325,730
+67% +$10.4M
GTH
58
DELISTED
Genetron Holdings Limited ADS
GTH
$23.2M 0.35%
557,298
-48,756
-8% -$2.25M
OYST
59
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$22.1M 0.33%
1,861,209
– –
WHWK
60
Whitehawk Therapeutics
WHWK
$271M
$21.3M 0.32%
+764,701
New +$23.3M
EPIX
61
DELISTED
ESSA Pharma
EPIX
$21.1M 0.32%
2,637,192
-416,727
-14% -$6.63M
ABUS icon
62
Arbutus Biopharma
ABUS
$915M
$20.3M 0.31%
4,733,323
-1,245,032
-21% -$4.15M
INMD icon
63
InMode
INMD
$880M
$19.9M 0.3%
249,998
– –
CERE
64
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$19.7M 0.3%
666,666
+166,666
+33% +$4.68M
RCOR
65
DELISTED
Renovacor, Inc.
RCOR
$19.3M 0.29%
2,187,540
+1,350,000
+161% +$13.2M
TELA icon
66
TELA Bio
TELA
$38.9M
$19M 0.29%
1,391,619
-815
-0.1% -$11.4K
LONA
67
LeonaBio Inc
LONA
$72.1M
$17.9M 0.27%
190,656
– –
ADVM
68
DELISTED
Adverum Biotechnologies
ADVM
$16.2M 0.24%
748,376
+12,584
+2% +$321K
NEO icon
69
NeoGenomics
NEO
$2.13B
$14.9M 0.22%
311,111
– –
URGN icon
70
UroGen Pharma
URGN
$2.29B
$14.4M 0.22%
+857,464
New +$13.6M
OSUR icon
71
OraSure Technologies
OSUR
$279M
$13.3M 0.2%
+1,174,722
New +$12.9M
BWAY
72
Brainsway
BWAY
$622M
$12.9M 0.19%
3,204,762
+400
+0% +$1.69K
IMUX icon
73
Immunic
IMUX
$195M
$12.1M 0.18%
137,081
+45,000
+49% +$4.43M
VINC
74
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$12.1M 0.18%
37,500
– –
XGN icon
75
Exagen
XGN
$166M
$11.2M 0.17%
821,414
– –
1 2
3
4 5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q3 2021 Portfolio in Review

As of Q3 2021, RTW Investments held 130 positions worth $6.63B, up 0.06% from $6.63B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

RTW Investments deployed $439M of net new capital in Q3 2021, opening 17 new positions and adding to 26 existing holdings. Its largest new stake was Thermo Fisher Scientific: 416,000 shares worth $238M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $74.8M trimmed.

  • RTW Investments's largest Q3 2021 buy was Thermo Fisher Scientific: 416,000 shares worth $238M.
  • RTW Investments added most to MacroGenics in Q3 2021, an estimated $34.4M increase.
  • RTW Investments's biggest Q3 2021 reduction was Protagonist Therapeutics, cutting an estimated $74.8M.
  • RTW Investments fully exited QuidelOrtho in Q3 2021, selling an estimated $113M.
  • RTW Investments's ten largest holdings make up 41% of its $6.63B portfolio in Q3 2021.
  • RTW Investments opened 17 new positions and closed 10 in Q3 2021.
  • RTW Investments's portfolio value rose 0.06% quarter-over-quarter to $6.63B.

Based on RTW Investments's 13F filing for Q3 2021, filed 15 Nov 2021.